An investigation has uncovered evidence of significant misreporting, raising new concerns about the approval and long-term use of ticagrelor over the past decade. In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has identified new concerns, this time focusing on key platelet studies that supported the drug’s approval by the FDA. For over […]



Summary

A new investigation by The BMJ reveals potential misreporting within key platelet studies that supported the FDA’s approval of ticagrelor, a multibillion-dollar drug, over the last decade. This investigation raises concerns about the validity of the data used to justify ticagrelor’s approval and its ongoing use, suggesting a need for further scrutiny of the drug’s benefits and risks. The specific nature of the misreporting remains undefined, but the article highlights its potential impact on regulatory decisions and patient safety.

Read more…

This post is part of “Science and Technology News”, Follow for more…!!!